11:37 AM EDT, 06/20/2024 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) entered into a pricing agreement for its cystic fibrosis drugs with the UK National Health Service, Bloomberg News reported Thursday, citing the country's drug pricing regulator, the National Institute for Health and Care Excellence.

The regulator, in its final draft guidance issued Thursday, recommended the Kaftrio, Symkevi and Orkambi drugs for patients with cystic fibrosis who have certain gene mutations, the report said.

The regulator called the drugs too expensive last year, Bloomberg reported.

Vertex didn't immediately respond to a request for comment from to MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 467.59, Change: +0.31, Percent Change: +0.07